AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16479390 — intervention group
Group type: COMPARATOR
Intervention: Control group (normally functioning kidneys)
Number of subjects: 35
Study 16479390 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (split GFR between 20 and 30 ml/min)
Number of subjects: 35
Study 15364875 — intervention group
Group type: EXPERIMENTAL
Intervention: TP10 (1, 3, 5, 10 mg/kg)
Number of subjects: 564
Study 15364875 — intervention group
Group type: EXPERIMENTAL
Intervention: TP10
Number of subjects: 564
Study 15364875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 10810824 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy plus lateral internal sphincterotomy (LIS)
Number of subjects: 42
Study 10810824 — intervention group
Group type: COMPARATOR
Intervention: Haemorrhoidectomy alone
Number of subjects: 42
Study 8841220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of saline plus epinephrine 1:200,000
Number of subjects: 60
Study 8841220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of bupivacaine 0.5% with epinephrine 1:200,000
Number of subjects: 60
Study 8841220 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule with mesosalpinx infiltration
Number of subjects: 60
Study 8841220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preoperative ketoprofen and mesosalpinx block
Number of subjects: 60
Study 1737967 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin
Number of subjects: 31
Study 1737967 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin
Number of subjects: 31
Study 1737967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1737967 — intervention group
Group type: COMPARATOR
Intervention: Placebo with niacin
Number of subjects: 31
Study 6741677 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week behavioral weight control program
Number of subjects: 36
Study 6741677 — intervention group
Group type: EXPERIMENTAL
Intervention: Program adherence post-treatment
Number of subjects: 36
Study 30922101 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ketamine infusion
Number of subjects: 41
Study 30922101 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ketamine infusions (six infusions administered thrice weekly over 2 weeks)
Number of subjects: 41
Study 30922101 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly maintenance infusions (four additional infusions administered once weekly)
Number of subjects: 41
Study 30922101 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active placebo control)
Number of subjects: 41
Study 28854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-call intervention (n = 236)
Number of subjects: 704
Study 28854569 — intervention group
Group type: EXPERIMENTAL
Intervention: One-call intervention (n = 233)
Number of subjects: 704
Study 28854569 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no additional treatment, n = 235)
Number of subjects: 704
Study 26386556 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational group interviewing-based safety education
Number of subjects: 70
Study 26386556 — intervention group
Group type: COMPARATOR
Intervention: Traditional educational sessions
Number of subjects: 70
Study 24843653 — intervention group
Group type: EXPERIMENTAL
Intervention: cilnidipine (10 mg/day)
Number of subjects: 19
Study 24843653 — intervention group
Group type: COMPARATOR
Intervention: azelnidipine (16 mg/day)
Number of subjects: 19
Study 21823344 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX + CoQ10
Number of subjects: 183
Study 21823344 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX
Number of subjects: 183
Study 21823344 — intervention group
Group type: COMPARATOR
Intervention: CoQ10
Number of subjects: 183
Study 19765233 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT ON
Number of subjects: 72
Study 19765233 — intervention group
Group type: COMPARATOR
Intervention: CRT OFF
Number of subjects: 72
Study 16625987 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic efavirenz capsule (Ranbaxy-Efavirenz)
Number of subjects: 41
Study 16625987 — intervention group
Group type: COMPARATOR
Intervention: Innovator efavirenz capsule (Sustiva)
Number of subjects: 41
Study 15541407 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (600 microg)
Number of subjects: 0
Study 15541407 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 microg)
Number of subjects: 0
Study 11421247 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 23
Study 11421247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9247181 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 mm HP (HP19)
Number of subjects: 65
Study 9247181 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mm HP (HP21)
Number of subjects: 65
Study 9247181 — intervention group
Group type: COMPARATOR
Intervention: 19 mm SJM (SJM19)
Number of subjects: 65
Study 9247181 — intervention group
Group type: COMPARATOR
Intervention: 21 mm SJM (SJM21)
Number of subjects: 65
Study 8329255 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.5 mg kg‐1
Number of subjects: 38
Study 8329255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3539508 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 methyl sulphonylamide
Number of subjects: 627
Study 3539508 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg PGE1 methyl ester
Number of subjects: 627
Study 3539508 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 9-methylene PGE2 free acid
Number of subjects: 627
Study 3539508 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg 15-methyl PGF2 alpha
Number of subjects: 627
Study 3539508 — intervention group
Group type: EXPERIMENTAL
Intervention: Single medium-sized laminaria tent
Number of subjects: 627
Study 29700350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 197
Study 29700350 — intervention group
Group type: COMPARATOR
Intervention: Menopause Education Control (MEC)
Number of subjects: 197
Study 27590313 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) - three 1 hour sessions per week
Number of subjects: 0
Study 27590313 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC) - three 30 minute walking sessions per week
Number of subjects: 0
Study 25282033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber setting
Number of subjects: 462
Study 25282033 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber setting
Number of subjects: 462
Study 22781527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group (n = 52)
Number of subjects: 102
Study 22781527 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 102
Study 20035347 — intervention group
Group type: EXPERIMENTAL
Intervention: P12 (12 mmHg)
Number of subjects: 67
Study 20035347 — intervention group
Group type: COMPARATOR
Intervention: P20 (20 mmHg)
Number of subjects: 67
Study 19065890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Shehuang Paste (SHP) and colonic dialysis with herbal medicine
Number of subjects: 120
Study 19065890 — intervention group
Group type: COMPARATOR
Intervention: Conventional basic therapy (placebo paste and colonic dialysis with normal saline)
Number of subjects: 120
Study 15755701 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1000000 KIU)
Number of subjects: 30
Study 15755701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gr)
Number of subjects: 30
Study 15755701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12587536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine-agonist therapy
Number of subjects: 87
Study 12587536 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 87
Study 12587536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (healthy controls and dopamine-agonist treated women)
Number of subjects: 87
Study 9673663 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided functional imaging with a portable robotic device generating forces
Number of subjects: 8
Study 9673663 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging results
Number of subjects: 8
Study 7640116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v. given 10 min before induction of anaesthesia
Number of subjects: 50
Study 7640116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v. group
Number of subjects: 50
Study 7640116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 7640116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 2751919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms
Number of subjects: 255
Study 2751919 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 255
Study 2751919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 797447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianhydrogalactitol (30 mg/m2/day for 5 days)
Number of subjects: 58
Study 797447 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 (130 mg/m2 on Days 1, 3, and 5)
Number of subjects: 58
Study 31980201 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc with XP-endo Finisher (XPF)
Number of subjects: 80
Study 31980201 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc without XP-endo Finisher (XPF)
Number of subjects: 80
Study 31980201 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next with XP-endo Finisher (XPF)
Number of subjects: 80
Study 31980201 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next without XP-endo Finisher (XPF)
Number of subjects: 80
Study 31980201 — intervention group
Group type: COMPARATOR
Intervention: CEC-Reciproc-XPF
Number of subjects: 80
Study 31980201 — intervention group
Group type: COMPARATOR
Intervention: TEC and CEC cavities
Number of subjects: 80
Study 31484582 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 200
Study 31484582 — intervention group
Group type: COMPARATOR
Intervention: Conventional administration of oxygen through a Venturi mask (Control)
Number of subjects: 200
Study 28504995 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) - 3 cycles: 5 minutes ischemia/5 minutes reperfusion induced by an ischemia cuff applied on the thigh
Number of subjects: 53
Study 28504995 — intervention group
Group type: COMPARATOR
Intervention: Control therapy without RIPC
Number of subjects: 53
Study 25888246 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2+ hormone receptor-positive (HR+) patients
Number of subjects: 1260
Study 25888246 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2+ hormone receptor-negative (HR-) patients
Number of subjects: 1260
Study 23503449 — intervention group
Group type: COMPARATOR
Intervention: Fasting conditions (400 mg posaconazole)
Number of subjects: 16
Study 23503449 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-fat meal (400 mg posaconazole)
Number of subjects: 16
Study 23503449 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (400 mg posaconazole)
Number of subjects: 16
Study 21810825 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care pocket-sized echocardiography (POCKET)
Number of subjects: 108
Study 19500403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 325
Study 19500403 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Number of subjects: 325
Study 19500403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBT and Physical Exercise
Number of subjects: 325
Study 19500403 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 325
Study 16448568 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 45
Study 16448568 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 14745853 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based oncology support program
Number of subjects: 169
Study 14745853 — intervention group
Group type: COMPARATOR
Intervention: High depression burden group
Number of subjects: 169
Study 14745853 — intervention group
Group type: COMPARATOR
Intervention: No depression burden group
Number of subjects: 169
Study 11126352 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy as part of an intervention program for childhood obesity, including behavior modification.
Number of subjects: 1322
Study 11126352 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1322
Study 9004827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 9004827 — intervention group
Group type: EXPERIMENTAL
Intervention: Actuarial approach to treatment benefits
Number of subjects: 0
Study 1562431 — intervention group
Group type: EXPERIMENTAL
Intervention: Slotted nails (Grosse‐Kempf nail and AO/ASIF universal femoral nail)
Number of subjects: 46
Study 1562431 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-slotted nails (Grosse‐Kempf nail)
Number of subjects: 46
Study 1562431 — intervention group
Group type: COMPARATOR
Intervention: Control bone
Number of subjects: 46
Study 1562431 — intervention group
Group type: EXPERIMENTAL
Intervention: Slotted nails
Number of subjects: 46
Study 1562431 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-slotted nails
Number of subjects: 46
Study 1562431 — intervention group
Group type: EXPERIMENTAL
Intervention: Slotted nails and Non-slotted nails
Number of subjects: 46
Study 2866134 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once at night
Number of subjects: 183
Study 2866134 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice daily
Number of subjects: 183
Study 2866134 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 183
Study 2866134 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 183
Study 31712013 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin analogue (PGA) monotherapy (control group)
Number of subjects: 87
Study 31712013 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout group (discontinue PGA monotherapy)
Number of subjects: 87
Study 29353367 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual clinical breast exam (CBE)
Number of subjects: 859
Study 29353367 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammogram
Number of subjects: 859
Study 29353367 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine source of care, confidence to use healthcare services, perceived expectations from family members and healthcare providers, motivation to comply with expectations
Number of subjects: 859
Study 29353367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-related access to care
Number of subjects: 859
Study 29353367 — intervention group
Group type: COMPARATOR
Intervention: Black YBCS
Number of subjects: 859
Study 28881339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 33
Study 28881339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 33
Study 28881339 — intervention group
Group type: COMPARATOR
Intervention: Baseline glomerular filtration rate (GFR)
Number of subjects: 33
Study 28881339 — intervention group
Group type: COMPARATOR
Intervention: Interstitial B- and T-cell infiltrates
Number of subjects: 33
Study 26314293 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 0
Study 26314293 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 0
Study 24573586 — intervention group
Group type: COMPARATOR
Intervention: Ligation with section of the saphenous arch (Group C)
Number of subjects: 45
Study 24573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple ligation of the saphenous vein without sectioning of its arch (Group L)
Number of subjects: 45
Study 21519282 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored behavioral intervention for nonadherence
Number of subjects: 14
Study 21519282 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 14
Study 18793584 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects model
Number of subjects: 0
Study 12875580 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (BH) 48 mg daily
Number of subjects: 52
Study 12875580 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine (FL) 10 mg daily
Number of subjects: 52
Study 11037800 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (Norpramin)
Number of subjects: 628
Study 11037800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (Lamictal)
Number of subjects: 628
Study 11037800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 8854285 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFA) supplementation (Linoleic acid 596 mg/day and alpha-linolenic acid 855 mg/day)
Number of subjects: 20
Study 8854285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 20
Study 1734694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% sodium tetradecyl sulfate (STD)
Number of subjects: 52
Study 1734694 — intervention group
Group type: COMPARATOR
Intervention: 1% polidocanol
Number of subjects: 52
Study 6716071 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute videotape induction
Number of subjects: 460
Study 6716071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet induction
Number of subjects: 460
Study 6716071 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 460
Study 2937638 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 12
Study 2937638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12
Study 2937638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30571591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 100
Study 30571591 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association diet
Number of subjects: 100
Study 26878676 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoaequorin
Number of subjects: 218
Study 26878676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 25789633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (ASA) prophylaxis
Number of subjects: 0
Study 25789633 — intervention group
Group type: COMPARATOR
Intervention: Control event rate (CERmin) and minimum event rate for treatment (MERT) approaches
Number of subjects: 0
Study 24278962 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect posterior composite resin restoration
Number of subjects: 29
Study 24278962 — intervention group
Group type: COMPARATOR
Intervention: Direct posterior composite resin restoration
Number of subjects: 29
Study 20667429 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide in oxygen
Number of subjects: 110
Study 20667429 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen (placebo)
Number of subjects: 110
Study 18405079 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomorphemic words
Number of subjects: 0
Study 18405079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefixed words
Number of subjects: 0
Study 18405079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefixed pseudo‐words
Number of subjects: 0
Study 18405079 — intervention group
Group type: EXPERIMENTAL
Intervention: Grammatical (word‐formation) rules
Number of subjects: 0
Study 16606390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing with AV search hysteresis (AVSH)
Number of subjects: 1530
Study 16606390 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber pacing (VVI)
Number of subjects: 1530
Study 16606390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing with AVSH
Number of subjects: 1530
Study 14509886 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrojugular approach (RJA)
Number of subjects: 100
Study 14509886 — intervention group
Group type: COMPARATOR
Intervention: Traditional (medial) approach
Number of subjects: 100
Study 11004426 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamicron(R)MR (30-120 mg/day)
Number of subjects: 800
Study 11004426 — intervention group
Group type: COMPARATOR
Intervention: Diamicron(R) (80-320 mg/day)
Number of subjects: 800
Study 11004426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 800
Study 8608520 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem plus vancomycin (500 mg every 6 hours of imipenem/cilastatin and 1 g every 12 hours of vancomycin)
Number of subjects: 300
Study 8608520 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam plus vancomycin (2 g every 6 hours of aztreonam and 1 g every 12 hours of vancomycin)
Number of subjects: 300
Study 8608520 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem regimen
Number of subjects: 300
Study 8608520 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam regimen
Number of subjects: 300
Study 1476032 — intervention group
Group type: EXPERIMENTAL
Intervention: Food hypersensitivity (identified by double-blind placebo-controlled food challenges)
Number of subjects: 320
Study 1476032 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-mediated mast cell and mononuclear cell activation
Number of subjects: 320
Study 6475712 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacing
Number of subjects: 50
Study 6475712 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 31818409 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and low‐dose dexamethasone
Number of subjects: 0
Study 31818409 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide and low‐dose dexamethasone
Number of subjects: 0
Study 27982160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 72